Tedisamil API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Tedisamil API 90961-53-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tedisamil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tedisamil
- Synonyms:
- Cas Number:
- 90961-53-8
- DrugBank number:
- DB06200
- Unique Ingredient Identifier:
- A5VAY2U3R8
General Description:
Tedisamil, identified by CAS number 90961-53-8, is a notable compound with significant therapeutic applications. Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Tedisamil functions by: It is hypothesized tedisamil prevents Ca2+ overload by the cAMP dependent SR Ca2+ uptake . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Tedisamil belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom, classified under the direct parent group Azaspirodecane derivatives. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Azaspirodecane derivatives class, specifically within the None subclass.
Categories:
Tedisamil is categorized under the following therapeutic classes: Antiarrhythmic agents, Antiarrhythmics, Class III, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cycloparaffins, Moderate Risk QTc-Prolonging Agents, Protective Agents, QTc Prolonging Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Tedisamil is a type of Anti-anginal agents
Anti-anginal agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) used for the treatment of angina, a condition characterized by chest pain or discomfort caused by reduced blood flow to the heart muscle. These APIs target the underlying cause of angina, which is often related to insufficient blood supply to the heart.
One commonly used anti-anginal agent is nitroglycerin, which belongs to the class of organic nitrates. Nitroglycerin works by dilating blood vessels, including the coronary arteries that supply blood to the heart. This dilation improves blood flow to the heart, relieving chest pain and reducing the workload on the heart.
Another class of anti-anginal agents is calcium channel blockers (CCBs). CCBs inhibit the movement of calcium ions into heart muscle cells and blood vessel walls. By doing so, they relax and widen blood vessels, enhancing blood flow to the heart and reducing the frequency and severity of angina episodes.
Beta blockers are also commonly used in the treatment of angina. These agents block the effects of adrenaline and other stress hormones on the heart, resulting in reduced heart rate and blood pressure. By slowing down the heart's activity, beta blockers decrease the demand for oxygen and reduce angina symptoms.
Anti-anginal agents play a crucial role in managing angina, providing relief to patients and improving their quality of life. It is important to consult with healthcare professionals for proper diagnosis, prescription, and usage of these pharmaceutical APIs to ensure safe and effective treatment of angina.
